These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28085275)

  • 1. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
    Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML
    J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.
    Corte JR; Yang W; Fang T; Wang Y; Osuna H; Lai A; Ewing WR; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Quan ML; Wexler RR; Lam PYS
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3833-3839. PubMed ID: 28687203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrocyclic factor XIa inhibitors.
    Wang C; Corte JR; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4056-4060. PubMed ID: 28780160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.
    Clark CG; Rossi KA; Corte JR; Fang T; Smallheer JM; De Lucca I; Nirschl DS; Orwat MJ; Pinto DJP; Hu Z; Wang Y; Yang W; Jeon Y; Ewing WR; Myers JE; Sheriff S; Lou Z; Bozarth JM; Wu Y; Rendina A; Harper T; Zheng J; Xin B; Xiang Q; Luettgen JM; Seiffert DA; Wexler RR; Lam PYS
    Bioorg Med Chem Lett; 2019 Oct; 29(19):126604. PubMed ID: 31445854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
    Fang T; Corte JR; Gilligan PJ; Jeon Y; Osuna H; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Wexler RR; Lam PYS
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126949. PubMed ID: 31932224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
    Corte JR; Pinto DJP; Fang T; Osuna H; Yang W; Wang Y; Lai A; Clark CG; Sun JH; Rampulla R; Mathur A; Kaspady M; Neithnadka PR; Li YC; Rossi KA; Myers JE; Sheriff S; Lou Z; Harper TW; Huang C; Zheng JJ; Bozarth JM; Wu Y; Wong PC; Crain EJ; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
    J Med Chem; 2020 Jan; 63(2):784-803. PubMed ID: 31833761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.
    Priestley ES; Cheney DL; DeLucca I; Wei A; Luettgen JM; Rendina AR; Wong PC; Wexler RR
    J Med Chem; 2015 Aug; 58(15):6225-36. PubMed ID: 26151189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridazine and pyridazinone derivatives as potent and selective factor XIa inhibitors.
    Hu Z; Wang C; Han W; Rossi KA; Bozarth JM; Wu Y; Sheriff S; Myers JE; Luettgen JM; Seiffert DA; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2018 Apr; 28(6):987-992. PubMed ID: 29501396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa.
    Hanessian S; Larsson A; Fex T; Knecht W; Blomberg N
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6925-8. PubMed ID: 21035339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design.
    Fjellström O; Akkaya S; Beisel HG; Eriksson PO; Erixon K; Gustafsson D; Jurva U; Kang D; Karis D; Knecht W; Nerme V; Nilsson I; Olsson T; Redzic A; Roth R; Sandmark J; Tigerström A; Öster L
    PLoS One; 2015; 10(1):e0113705. PubMed ID: 25629509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.
    Yang W; Wang Y; Lai A; Clark CG; Corte JR; Fang T; Gilligan PJ; Jeon Y; Pabbisetty KB; Rampulla RA; Mathur A; Kaspady M; Neithnadka PR; Arumugam A; Raju S; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Chacko SA; Bozarth JM; Wu Y; Crain EJ; Wong PC; Seiffert DA; Luettgen JM; Lam PYS; Wexler RR; Ewing WR
    J Med Chem; 2020 Jul; 63(13):7226-7242. PubMed ID: 32456431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-Based Lead Generation of 5-Phenyl-1
    Wei Q; Zheng Z; Zhang S; Zheng X; Meng F; Yuan J; Xu Y; Huang C
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30103465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutral macrocyclic factor VIIa inhibitors.
    Wurtz NR; Parkhurst BL; DeLucca I; Glunz PW; Jiang W; Zhang X; Cheney DL; Bozarth JM; Rendina AR; Wei A; Harper T; Luettgen JM; Wu Y; Wong PC; Seiffert DA; Wexler RR; Priestley ES
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2650-2654. PubMed ID: 28460818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel phenylalanine derived diamides as Factor XIa inhibitors.
    Smith LM; Orwat MJ; Hu Z; Han W; Wang C; Rossi KA; Gilligan PJ; Pabbisetty KB; Osuna H; Corte JR; Rendina AR; Luettgen JM; Wong PC; Narayanan R; Harper TW; Bozarth JM; Crain EJ; Wei A; Ramamurthy V; Morin PE; Xin B; Zheng J; Seiffert DA; Quan ML; Lam PYS; Wexler RR; Pinto DJP
    Bioorg Med Chem Lett; 2016 Jan; 26(2):472-478. PubMed ID: 26704266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.
    Al-Horani RA; Ponnusamy P; Mehta AY; Gailani D; Desai UR
    J Med Chem; 2013 Feb; 56(3):867-78. PubMed ID: 23316863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric Synthesis of Silanediol Inhibitors for the Serine Protease Coagulation Cascade Enzyme FXIa.
    Duong HQ; Sieburth SM
    J Org Chem; 2018 May; 83(10):5398-5409. PubMed ID: 29667397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atropisomer Control in Macrocyclic Factor VIIa Inhibitors.
    Glunz PW; Mueller L; Cheney DL; Ladziata V; Zou Y; Wurtz NR; Wei A; Wong PC; Wexler RR; Priestley ES
    J Med Chem; 2016 Apr; 59(8):4007-18. PubMed ID: 27015008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and in vitro biological evaluation of aryl boronic acids as potential inhibitors of factor XIa.
    Lazarova TI; Jin L; Rynkiewicz M; Gorga JC; Bibbins F; Meyers HV; Babine R; Strickler J
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5022-7. PubMed ID: 16876411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.